UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/762,421	01/22/2004	Paul Ashton	CDSI-P01-040	4529
28120 ROPES & GRA	7590 07/31/200 AY LLP	EXAMINER		
PATENT DOC		SASAN, ARADHANA		
BOSTON, MA	ATIONAL PLACE 02110-2624		ART UNIT	PAPER NUMBER
			1615	
			MAIL DATE	DELIVERY MODE
			07/31/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/762,421	ASHTON ET AL.	
Examiner	Art Unit	
ARADHANA SASAN	1615	

	ARADHANA SASAN	1615					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
THE REPLY FILED 19 June 2008 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.							
1. A The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:							
a) X The period for reply expires 3 months from the mailing date of the final rejection.							
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.							
Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).							
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL							
2. The Notice of Appeal was filed on 19 June 2008. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).							
AMENDMENTS	e med within the time period set for	(a)	•				
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below);							
 (b) ☐ They raise the issue of new matter (see NOTE below); (c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or 							
(d) ☐ They present additional claims without canceling a d	corresponding number of finally reje	ected claims.					
NOTE: (See 37 CFR 1.116 and 41.33(a)).							
4. The amendments are not in compliance with 37 CFR 1.12		mpliant Amendment (l	PTOL-324).				
5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the							
non-allowable claim(s).							
7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows:							
Claim(s) allowed:							
Claim(s) objected to: Claim(s) rejected: <u>1-3,10,14,16-18,20 and 21</u> .							
Claim(s) rejected: <u>1-3,10,14,10-16,20 and 21.</u> Claim(s) withdrawn from consideration: <u>4-9 and 11-13.</u>							
AFFIDAVIT OR OTHER EVIDENCE							
8. The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).							
9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will <u>not</u> be entered because the affidavit or other evidence failed to overcome <u>all</u> rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).							
10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER							
11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: <u>See Continuation Sheet.</u>							
12. Note the attached Information <i>Disclosure Statement</i> (s). (PTO/SB/08) Paper No(s)							
<u> </u>							

Continuation of 11. does NOT place the application in condition for allowance because: Applicant's arguments (filed 6/19/08) have been fully considered but are not found persuasive. The limitation of the one or more additional coatings that "comprise a carbonic anhydrase inhibitor that is the same or different as the carbonic anhydrase inhibitor of the inner drug core" in the amendments to claims 1, 2, 14 and 18 was not present in the previous set of claims. This limitation raises new issues that would require further consideration and/or search.

/MP WOODWARD/ Supervisory Patent Examiner, Art Unit 1615